Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.45 |
| ▸ | ABL1 | P00519 | 9/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5502653 | 0.83 | ABL1 (0.45) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| Hydrazine SCHEMBL21402121 | 0.82 | ABL1 (0.46) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| SCHEMBL5500764 | 0.81 | IRAK4 (0.55) | IRAK4ABL1MAP4K1BRAF | |
| SCHEMBL14568512 | 0.81 | IRAK4 (0.55) | IRAK4ABL1MAP4K1BRAF | |
| Methylamine SCHEMBL21402118 | 0.80 | ABL1 (0.46) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| Ammonia Solution, Strong SCHEMBL5503341 | 0.80 | ABL1 (0.44) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| Ammonia Solution, Strong SCHEMBL5498296 | 0.76 | ABL1 (0.43) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| SCHEMBL4733367 | 0.71 | LCK (0.70) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| SCHEMBL30494215 | 0.71 | LCK (0.70) | ABL1MAP4K1CYP11B1CYP11B2KIT | |
| SCHEMBL5498511 | 0.68 | RIPK2 (0.52) | ABL1MAP4K1KITPDGFRABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | IRAK4 28/4885ABL1 32/4885MAP4K1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.